Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure

Go back to Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure

Sanuwave Health Updates Second Quarter 2026 Guidance

June 16, 2026 8:00 AM EDT

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million

Company on pace for record unit sales of applicators in Q2

Market disruption impacting Ultramist system sales

EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5... More